You just read:

European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy

News provided by

Lexicon Pharmaceuticals, Inc.

Sep 19, 2017, 12:33 ET